Jan 30, 2017 8:30 am EST EyeGate Pharma Announces Positive Top-line Data from First-in-Human Pilot Trial of Ocular Bandage Gel in Corneal Epithelial Defects
Jan 24, 2017 8:30 am EST EyeGate Pharmaceuticals to Present at the Noble Financial Capital Markets’ 13th Annual Investor Conference
Jan 23, 2017 8:30 am EST EyeGate Pharma Awarded Canadian Patent for Proprietary Iontophoretic Formulation and Use of the Formulation for Ocular Delivery of Dexamethasone Phosphate
Jan 9, 2017 8:30 am EST EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437
Dec 5, 2016 8:30 am EST EyeGate Reports Positive Data from Third Stage of Phase 1b/2a Clinical Trial of EGP-437 in Cataract Surgery Patients
Nov 17, 2016 4:01 pm EST FDA Confirms a 510(k) De Novo Path for EyeGate’s Device, the Ocular Bandage Gel, Following Pre-Submission Meeting
Nov 2, 2016 9:20 am EDT EyeGate Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update
Sep 13, 2016 8:30 am EDT EyeGate Awarded $448,185 for second year of funding of Phase II SBIR Grant from U.S. Department of Defense